The Bedford, Mass.-based company posted a net loss of -$17.4 million, or -42¢ per share, on sales of $504,000 for the three months ended Dec. 31, for sales growth of 3.5% compared with the same period last year.
Earnings per share were -42¢, just behind consensus on The Street. But Ocular narrowly beat sales estimates; analysts were looking for sales of $480,000.
For the full year, the company posted a net loss of -$59.1 million on sales of $1.99 million. Full-year revenues were up 3.5% compared to 2017.
“2018 was a transformational year for Ocular highlighted by the U.S. Food and Drug Administration’s approval of Dextenza, our dexamethasone intracanalicular insert for the treatment of post-surgical ocular pain,” president & CEO Antony Mattessich said in prepared remarks. “This accomplishment brings us one step closer to realizing the significant potential of our hydrogel drug-delivery platform. We are at a critical moment for the company as we are on the cusp of becoming a fully-integrated, commercial-stage biopharmaceutical company. We remain on track to launch Dextenza by mid-year.
“We are also pleased with the early momentum we are seeing as we enter 2019, having filed a supplemental New Drug Application to expand the Dextenza label for the treatment of ocular inflammation and recently closing a $37.5 million convertible debt financing which strengthens our cash position and extends our runway into early 2020. Lastly, our pipeline continues to progress and we remain on track to present top-line data from our first Phase 3 pivotal trial of OTX-TP in the first half of this year. Our two Phase 1 programs are also progressing well with the dosing of our second patient in the OTX-TKI trial in wet Age-Related Macular Degeneration (wet AMD) and the continuing enrollment of patients in our second cohort in our OTX-TIC program in glaucoma,” Mattessich added.
OCUL shares were down -21.2% to $3.45 apiece in premarket activity today.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.